January 7, 2019 12:14 PM EST

Prepping a cross-Pacific move, OrbiMed-backed Apollomics bags $100M Series B for I/O combos

Amber Tong

Senior Editor

Guo-Liang Yu has big plans mapped out for Apollomics in 2019: Move the biotech’s headquarters from Hangzhou, China to Foster City, CA; scout new assets to add to its pipeline, currently led by c-Met/PD-1 combo; and build up the team to run a trans-Pacific operation. With support from a well-heeled Chinese backer, he now has $100 million to bankroll all that.

OrbiMed Asia, where Yu is a partner, got the company started in 2016 with a modest $9.75 million Series A, back when it was named CBT Pharmaceuticals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Prepping a cross-Pacific move, OrbiMed-backed Apollomics bags $100M Series B for I/O combos

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Senators want to know more on why Novo is discontinuing its insulin Levemir

Prep­ping a cross-Pa­cif­ic move, Or­biMed-backed Apol­lomics bags $100M Se­ries B for I/O com­bos

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

Prepping a cross-Pacific move, OrbiMed-backed Apollomics bags $100M Series B for I/O combos

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Senators want to know more on why Novo is discontinuing its insulin Levemir